Sir,
We read with interest the reply of Fuentes-Alexandro et al. 1 to the report of Bert et al. 2 on transcatheter aortic valve replacement (TAVR) in patients for advanced valvular disease in active systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). The authors raise several issues to open the discussion of a topic, concerned with a very specific subset of patients undergoing TAVR procedure. Apparently, conventional aortic valve surgery represents a high risk for patients with autoimmune disease. Arguments pro and con concerning various types of aortic valve replacement can be found. We performed a review on 77 well-documented patients (including two of our own patients) with autoimmune disease and aortic valve surgery between 1966 and 2013. 3 First, patients with autoimmune disease who require aortic valve replacement are predominately young patients, such as in several subsets we investigated, namely patients with SLE and patients with granulomatous disease. However, since the durability of biological valves is more problematic in young, active patients (and even more so in the mitral position), and long-term results for TAVR are not available, this type of valve is presently recommended only for older high-risk patients. Secondly, the durability of all biological valves, including TAVR valves, in the presence of an autoimmune process is combined with a high risk of pannus formation, leakage and low cardiac output (LCO), which accounted for 13% of the postoperative morbidity. Furthermore, chronic immunosuppressive treatment increased the perioperative risk of delayed wound healing, wound infections, higher blood loss and prolonged malfunction of organs after cardiopulmonary bypass. Thus, despite their young age, the mortality of 15.4% and the major morbidity of 30.8% of these patients during a period of seven years after open aortic valve replacement were high. These rates were also, to a lesser extent, elevated in patients with granulomatous disease. Currently, there are no available data facilitating decision making for patients with autoimmune disease undergoing aortic valve replacement. Only the Society of Thoracic Surgeons (STS) score, which includes immunosuppressive treatment (of any kind) as an independent risk factor, provides an informative estimation of perioperative risk. The durability of biological valves in this group of patients is also a source of concern and needs specific investigation. Thirdly, certain subgroups of SLE patients needed higher anticoagulant treatment. These included patients with secondary APS and especially patients with primary APS and patients with prosthesis in the mitral position. All these patients are known for a high thromboembolic risk, particularly of prosthetic valve thrombosis, stroke and peripheral thromboembolism. Our two young patients received a mechanical valve and, with an international normalized ratio (INR) of 3 (granulomatous disease) to 3.5 (SLE with secondary APS), remained without any valve-related complications 10 years postoperatively.
The concept of a less-invasive TAVR procedure in patients with autoimmune disease may reduce certain risks, but the risk of complications due to wall fragility remains to be minimized. 4 However, technical improvements of delivery systems allowing articulation of the catheter tend to minimize friction with the aortic wall. Furthermore, the evolution in valve design aims to reduce the occurrence of relevant aortic regurgitation. All these features render TAVR an attractive alternative for intermediate-risk patients and younger patients with relevant comorbidities. Some patients with granulomatous disease and aortic (annulus) dilation needed an aortic root repair or a Bentall procedure. However, innovative ideas, such as external aortic ring annuloplasty using ExtraAortic TM (CORONEO Inc), aim for reduction of invasiveness. 5 Since the number of patients with aortic valve autoimmune disease is low, prospectively randomized, multicenter trials and registries are needed to standardize the surgical treatment of patients with autoimmune disease and to formulate guidelines in the future. In this context, the importance of the Heart Team needs to be stressed since the decision concerning the type of valve to be implanted should be individualized considering prognosis and activity of the underlying autoimmune disease, age, comorbidities, as well as
